Selank
A synthetic heptapeptide anxiolytic developed in Russia by modifying the endogenous immunopeptide tuftsin, offering cognitive enhancement without sedation.
Also known as: TP-7, Selanc
Regulatory Status
Classification date: 2026-02-27
Reclassification to Category 1 announced but not yet formalized
Compounding: Not currently available for compounding
Evidence Summary
Key Studies
- Selank administration affects the expression of genes related to neurotransmission in rat hippocampus
- Anxiolytic-like action of selank: involvement of the GABA-benzodiazepine receptor complex
- The effect of selank on cognitive function, anxiety, and depression in patients with generalized anxiety disorder
How It Works
Selank is a synthetic analog of tuftsin (threonyl-lysyl-prolyl-arginine) with a stabilizing Pro-Gly-Pro tail. It modulates GABA-ergic and serotonergic neurotransmission, increasing BDNF expression in the hippocampus and influencing the expression of over 50 genes related to inflammation and neurotransmitter function. It has been approved in Russia as an anxiolytic and nootropic. Unlike benzodiazepines, it does not cause sedation, cognitive impairment, or dependence.
Common Applications
Safety & Considerations
Well tolerated in Russian clinical studies with no reported significant adverse effects. Available as a nasal spray. No sedative, addictive, or withdrawal properties documented. Limited Western clinical trial data. May interact with other anxiolytic medications. Currently not legal for compounding in the US.
Related Research
Regulatory classifications can change rapidly. The information shown here was last verified on 2026-02-27. Always confirm current legal status with a licensed provider or the FDA before making treatment decisions.